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Background: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease
hallmarked by irreversible damage of cartilage and bone. Matrix metalloproteinases
(MMPs) involved in connective tissue remodeling play an important role in this process.
Numerous MMPs have been examined in humans and animals, but their functions are
still not fully understood. Therefore, we investigated the role of MMPs in the K/BxN
serum-transfer model of RA with the broad-spectrum MMP inhibitor subantimicrobial
dose doxycycline (SDD) using complex in vivo and in vitro methodolgy.
Methods: Chronic arthritis was induced by repetitive i.p. injections of K/BxN serum in
C57BL/6J mice. SDD was administered daily in acidified drinking water (0.5 mg/mL,
80 mg/kg) during the 30 days experimental period. Mechanonociceptive threshold
of the paw was evaluated by aesthesiometry, grasping ability by grid test, arthritis
severity by scoring, neutrophil myeloperoxidase activity by luminescence, vascular
hyperpermeability and MMP activity by fluorescence in vivo imaging and the latter also
by gelatin zymography, bone structure by micro-computed tomography (micro-CT).
Plasma concentrations of doxycycline were determined by liquid chromatography-mass
spectrometry analysis.
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Results: K/BxN serum induced significant inflammatory signs, mechanical
hyperalgesia, joint function impairment, increased myeloperoxidase activity and
vascular hyperpermeability. Significant increase of MMP activity was also observed both
in vivo and ex vivo with elevation of the 57–60, 75, and 92 kDa gelatinolytic isoforms in
the arthritic ankle joints, but neither MMP activity nor any above described functional
parameters were influenced by SDD. Most importantly, SDD significantly reduced
bone mineral density in the distal tibia and enhanced the Euler number in the ankle.
Arthritis-induced microarchitectural alterations demonstrating increased irregularity and
cancellous bone remodeling, such as increased Euler number was significantly elevated
by SDD in both regions.
Conclusion: We showed increase of various MMP activities in the joints by in vivo
fluorescence imaging together with ex vivo zymography, and investigated their functional
significance using the broad-spectrum MMP inhibitor SDD in the translational RA
model. This is the first demonstration that SDD worsens arthritis-induced bone
microarchitectural alterations, but it appears to be independent of MMP inhibition.
Keywords: rheumatoid arthritis, matrix metalloproteinases, K/BxN serum-transfer arthritis, subantimicrobial dose
doxycycline, bone homeostasis, in vivo optical imaging, micro-CT, gelatin zymography
INTRODUCTION
Rheumatoid arthritis (RA) is a progressive, chronic inflammatory
joint disease leading to irreversible articular cartilage and bone
destruction. It is one of the most common musculoskeletal
disorder causing physical disability with a worldwide prevalence
of approximately 1% (Gibofsky, 2012). Despite the therapeutic
revolution in the last decades, the treatment of RA is not
fully resolved. Although the novel biologics can significantly
reduce synovitis and structural progression, they are far from
being ideal drugs due to their high costs, ineffectiveness for
chronic pain and sometimes serious side effects resulting
from immunosuppression (Smolen et al., 2016; McWilliams
and Walsh, 2017). Therefore, further research is needed to
precisely explore its pathophysiological mechanisms, identify
crucial mediators, and find new potential drug targets. These may
include matrix metalloproteinases (MMPs), which are important
players of joint damage in arthritic conditions, most importantly
in RA (Rose and Kooyman, 2016).
MMPs are secreted or membrane-bound enzymes involved
in the family of calcium- and zinc-dependent endopeptidases.
Their major function is degrading the extracellular matrix,
but they are also capable of cleaving certain non-matrix
peptides (e.g., cytokines, chemokines, growth factors, cell
surface receptors etc.) (Van Lint and Libert, 2007; Fingleton,
2017). They have crucial roles in physiological regulation
of embryonic development, tissue remodeling and wound
Abbreviations: ANOVA, analysis of variance; CIA, collagen-induced
arthritis; CT, computed tomography; Dkk-1, Dickkopf-related protein 1;
I.p., intraperitoneal; LC-MS, liquid chromatography-mass spectrometry; MMP,
matrix metalloproteinase; MPO, myeloperoxidase; MT, membrane-type; OA,
osteoarthritis; PGE2, prostaglandin E2; PLA2, phospholipase A2; RA, rheumatoid
arthritis; ROI, region of interests; SDD, subantimicrobial dose doxycycline; SF,
synovial fluid; ST, synovial tissue.
healing. Furthermore, they are involved in several patho-
physiological processes, mainly in “collagenolytic” diseases
associated with connective tissue destruction (e.g., arthritic
diseases, cancer, atherosclerosis, pulmonary emphysema, chronic
inflammatory skin diseases etc.) (Tokito and Jougasaki, 2016;
Amar et al., 2017).
The most investigated MMPs in RA are collagenases (MMP-1,
MMP-8 and MMP-13), gelatinases (MMP-2 and MMP-9),
MMP-3 from stromelysins and MMP-14 from membrane-type
(MT) MMPs (Rose and Kooyman, 2016). MMP-1 (interstitial
collagenase or human fibroblast collagenase) is a ubiquitously
expressed collagenase, which is the earliest MMP excessively
produced under several pathological circumstances (Burrage,
2006; Shi et al., 2012). In RA it is originated from the synovium
and the cartilage, and together with MMP-3 (stromelysin-1)
they have been considered to be useful biomarkers for early
diagnosis, disease activity and therapeutic efficacy (Green
et al., 2003; Fiedorczyk et al., 2006). MMP-8 (collagenase-2
or neutrophil collagenase) is produced mainly by neutrophils,
but is also expressed in chondrocytes and synovial fibroblasts.
Surprisingly, its role is clearly protective in arthritic tissues
confirmed by studies using MMP-8-deficient mice (Cox et al.,
2010; Garcia et al., 2010). MMP-13 (collagenase-3) is expressed
predominantly in the chondrocytes and cleaves most efficiently
the type II collagen, which is the main matrix component of
the articular cartilage. Therefore, it is not surprising to be a
potential therapeutic target in RA and osteoarthritis (OA) (Singh
et al., 2013). Expression of MMP-2 (gelatinase A) and MMP-9
(gelatinase B) are also elevated in arthritis (Dreier et al., 2004;
Duerr et al., 2004), but interestingly they have distinct roles in
RA. MMP-2 knockout mice showed significantly increased, while
MMP-9-deficient ones significantly reduced severity of arthritis
in comparison with their wildtypes, suggesting a protective
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and a deleterious role of these enzymes in collagen antibody-
induced arthritis, respectively (Itoh et al., 2002). Among the MT-
MMPs, MMP-14 (MT1-MMP) plays predominant role in joint
disorders. It is overexpressed in arthritic cartilage, fibroblasts
and osteoclasts activating also proMMP-2 and proMMP-13,
mediating bone resorption and promoting proinflammatory gene
expression in macrophages (Burrage, 2006; Rose and Kooyman,
2016; Fingleton, 2017).
Although the role of the abovementioned MMPs has
already been examined in several experimental arthritis models,
surprisingly there are only two studies focusing on MMPs
(MMP-8 and -13) in the K/BxN serum-transfer murine arthritis,
which is one of the most translational RA model (Garcia et al.,
2010; Singh et al., 2013). This is a commonly used inducible
model of RA, in which transient polyarthritis is evoked in
healthy recipients by passive transfer of arthritogenic serum
originating from a spontaneously arthritic transgenic mouse
strain. The serum contains primarily anti-glucose-6-phosphate
isomerase antibodies, which form immune complexes and
trigger RA-like joint inflammation and destruction (Korganow
et al., 1999). The main advantages of this model are that
it is suitable for studying the B- and T-cell independent
immunological mechanisms and in case of repeated serum
injection the RA-associated chronic pain with neuropathic
components (Korganow et al., 1999; Christianson et al.,
2010). Although the pharmacological interventions with MMP
inhibitors are also valuable tools to examine the roles of MMPs,
in this model their functions had only been studied using
specific knockout mice.
Therefore, we investigated the activity and roles of MMPs in
the K/BxN serum-transfer arthritis model with the non-selective
MMP inhibitor subantimicrobial dose doxycycline (SDD) using
a complex in vivo and in vitro methodolgy. In the present
study we showed the increase of various MMP activities in the
joints by in vivo fluorescence imaging together with ex vivo
zymography, as well as demonstrated for the first time that SDD
worsens arthritis-induced bone microarchitectural alterations
most probably independently of MMP inhibition.
MATERIALS AND METHODS
Animals
Experiments were carried out on 12–20 weeks old male
C57BL/6J mice weighing 20–30 g. They were bred and kept
in the Laboratory Animal House of the Department of
Pharmacology and Pharmacotherapy, University of Pécs in
325 × 170 × 140 mm sized cages under a 12 h light/dark
cycle at 24–25 ◦C, provided with standard mouse chow and
water ad libitum. The total number of animals used in the
experiments were 33 (17 in the 30 days and 16 in the 16 days
experimental series).
Ethics Statement
All experiments were performed according to European
legislation (Directive 2010/63/EU) and Hungarian Government
regulation (40/2013., II. 14.) on the protection of animals used
for scientific purposes, complied with the recommendations of
the International Association for the Study of Pain. The studies
were approved by the Ethics Committee on Animal Research of
University of Pécs (license No.: BA 02/2000–2/2012).
Induction of the Arthritis
Arthritis was induced by repeated intraperitoneal (i.p.) injection
of 150 µL of arthritogenic K/BxN serum on the days 0, 3, 10,
and 20. Repeated administration was applied to evoke more
persistent, long-lasting arthritis. K/BxN sera were obtained from
the spontaneously arthritic transgenic K/BxN mice bred and
kept in the Animal House of the Department of Physiology,
Semmelweis University, Budapest, Hungary. Control animals
received non-arthritogenic BxN serum from healthy BxN
littermates of K/BxN animals following the same protocols
(Borbély et al., 2015).
Preparation of Doxycycline-Treated
Drinking Water
Doxycycline was administered in subantimicrobial dose (below
100 mg/kg), therefore 100 mg doxycycline hyclate (Sigma-
Aldrich, St. Louis, MO, United States) was dissolved in 200 mL
acidified water (0.5 mg/mL). Since there are no data for chronic
doxycycline use in arthritis, the dosage and concentration were
based on earlier publications related to other issues (Prall et al.,
2002; Marx et al., 2014). The estimated daily consumption
of an adult mouse was 5 mL resulting in an approximately
80–85 mg/kg oral dose. To avoid the precipitate formation
and reach the expected doxycycline plasma concentration, the
water was acidified to pH of 3.2 with 37% hydrochloric acid
(Merck, Darmstadt, Germany). The pH of the drinking water
was measured by Radelkis Laboratory Digital OP-211 pH meter
(Radelkis Ltd., Budapest, Hungary). Mice provided with acidified
tap water were used for controls. The water was maintained
in standard, clear mouse water bottles (250 mL; Acéllabor
Ltd., Vecsés, Hungary) placed in complete mouse cage setups
and covered with aluminum foil to prevent the photolysis of
doxycycline. All water bottles were changed every other day by
the research staff.
Experimental Design
The study was performed in two series as outlined in Figure 1.
Daily doxycycline treatment (approximately 80 mg/kg, p.o.)
was started on day 0 and continued until day 30 in the first
and until day 16 in the second series. The mechanonociceptive
threshold of the hind paws were evaluated on days 5, 9,
15, and 24, neutrophil myeloperoxidase (MPO) activity and
plasma extravasation on days 2, 8, 14, and 21, MMP activity
on day 4, changes of the periarticular bone structure on
day 30, arthritis severity and joint function every day during
the 30 days experimental period. Following the micro-computed
tomography (micro-CT) analysis, animals were euthanized,
blood samples were collected for plasma concentration analyis
of doxycycline and ankle joints were removed for gelatin
zymography. Water consumption was checked every other day,
while body weight was measured every day.
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FIGURE 1 | Schematic drawing describing the experimental design of K/BxN serum-transfer arthritis model.
Evaluation of Disease Severity
Visible arthritic signs (hind limb edema and hyperemia)
were semiquantitatively scored using a scale of 0–10 (0–1.5:
healthy, 1.5–2.5: minimal signs referred to disease, 2.5–4:
mild inflammation, 4–7: moderate inflammation, 7–10: severe
inflammation) (Jakus et al., 2009; Horvath et al., 2017).
Evaluation of Mechanonociception
The dynamic plantar aesthesiometer (Ugo Basile 37400, Comerio,
Italy) was used for the assessment of the mechanosensitivity of
plantar surface of the hind paw. Mice were placed into acrylic
glass boxes with wire grid floor, then after acclimation the plantar
surface was touched with a straight metal filament lifting with
increasing upward force (maximum force of 10 g with 4 s latency)
until the animal withdrew his paw. Mechanical hyperalgesia was
represented as a percentage decrease of the initial (before serum
injection) withdrawal thresholds (Horvath et al., 2016).
Evaluation of Joint Function
The grasping ability correlating with joint function was
determined using the grid test in the K/BxN serum-transfer
arthritis model. Mice were placed on a horizontal wire grid, then
it was turned over and the latency to fall was determined. The
grid was maintained in horizontal position for a maximum of 20 s
(Jakus et al., 2009).
In vivo Bioluminescence Imaging of
Neutrophil MPO Activity
Neutrophil MPO-derived reactive oxygen species (ROS)
production and the enzyme activity were assessed with
luminol-derived bioluminescence. Luminol (5-amino-2,3-
dihydro-1,4-phthalazine-dione) sodium salt (150 mg/kg, Gold
Biotechnology, Olivette, MO, United States) dissolved in sterile
phosphate buffered saline (PBS, 30 mg/mL) was injected i.p.
into anesthetized mice. They were anesthetized using ketamine
(120 mg/kg i.p.; Calypsol, Gedeon Richter Plc., Budapest,
Hungary) and xylazine (6 mg/kg i.p.; Sedaxylan, Eurovet Animal
Health B.V., Bladel, Netherlands). Bioluminescence imaging
was performed 10 min post-injection using the IVIS Lumina II
(PerkinElmer, Waltham, MA, United States; 120 s acquisition,
Binning = 8, F/Stop = 1). Identical Region of Interests (ROIs)
were applied around the ankles and luminescence was expressed
as total radiance (total photon flux/s) (Botz et al., 2014).
In vivo Fluorescence Imaging of
Plasma Extravasation
Plasma extravasation was visualized by IR-676-based
fluorescence imaging. IR-676 vascular fluorescent dye
(0.5 mg/kg, Spectrum-Info Ltd., Kyiv, Ukraine) dissolved in
5% (v/v) aqueous solution of Kolliphor HS 15 (polyethylene-
glycol-15-hydroxystearate; Sigma-Aldrich, St. Louis, MO,
United States) was injected intravenously (i.v.) into anesthetized
mice (120/6 mg/kg ketamine-xylazine i.p.). Fluorescence
imaging was performed 20 min post-injection using the IVIS
Lumina II (PerkinElmer, Waltham, MA, United States; auto
acquisition time, Binning = 8, F/stop = 2, excitation/emission
filter: 640/700 nm). Data were analyzed and ROIs were drawn
around the ankle joints. Fluorescence was expressed as radiant
efficiency ([photons/s/cm2/sr]/[µW/cm2]) (Botz et al., 2015).
In vivo Fluorescence Imaging of
MMP Activity
MMP activity was assessed in vivo using MMPSense 750
FAST (PerkinElmer, Waltham, MA, United States), an
activatable fluorescent imaging agent for MMP-2, -3, -7, -9,
-12, and -13 according to the manufacturer’s instructions
(2 nmol/subject i.v.). Measurements were performed with IVIS
Lumina II (PerkinElmer, Waltham, MA, United States; auto
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acquisition time, Binning = 2, F/stop = 1, excitation/emission
filter: 745/800 nm) 6 h later. ROIs were applied around the
ankles and fluorescence was expressed as radiant efficiency
([photons/s/cm2/sr]/[µW/cm2]) (Borbély et al., 2015).
In vivo Micro-CT Analysis of the
Region of Ankle Joints
Micro-CT imaging was performed in a self-control manner
before and 30 days after the induction of arthritis. The
quantitative values calculated from the pictures at the end of
the study were compared to the initial images of the same mice
before the experiment. The right ankle joints were scanned using
a 17.5 µm voxel size by a SkyScan 1176 in vivo micro-CT
(Bruker, Kontich, Belgium). After reconstruction of the scans the
bone structural changes were evaluated using the CT Analyser R©
software. Standardized ROIs were drawn around the periarticular
region of the distal tibia and fibula, as well as the ankle including
both the tibio-tarsal and tarso-metatarsal joints. In these ROIs
bone mineral density, bone surface density, number of pores,
volume of open pores, percent increase of open pore volume, and
the Euler number, a measure of trabecular connectedness were
evaluated (Borbély et al., 2015).
Detection of MMP Activities by
Gelatin Zymography
At the end of both series of the experiment, on days 16 and 30,
mice were euthanized with sodium pentobarbital (100 mg/kg i.p.;
Euthanimal, Alfasan Nederland B.V., Woerden, Netherlands)
and ankle joints were removed to assess MMP activities. First
the ankle joints were homogenized in a 4 times volume of
homogenization buffer containing 50 mM Tris base (Merck,
Darmstadt, Germany) and 1 mL 0.5% Triton (Sigma-Aldrich,
St. Louis, MO, United States) dissolved in 500 mL distilled
water for 2 × 10 s at 20,000 rpm with T25 digital ULTRA-
TURRAX homogenizer (IKA-Werke GmbH&Co. KG, Staufen,
Germany). Than the joint homogenates were centrifuged at 4◦C
for 10 min at 10,000 rpm and the supernatants were collected
for gelatin zymography. Gelatinolytic activities of MMPs were
examined as previously described (Bencsik et al., 2014, 2015).
Briefly, 8% polyacrylamide gels were copolymerized with gelatin
(2 mg/mL, type A from porcine skin, Sigma-Aldrich, St. Louis,
MO, United States), and 25µg of protein per lane was loaded. An
internal standard (American Type Culture Collection, Manassas,
VA, United States) was loaded into each gel to normalize activities
between gels. After electrophoresis (90 V, 90 min), gels were
washed with zymogram renaturation buffer (Novex, Carlsbad,
CA, United States) for 40 min. Samples were incubated for 20 h
at 37◦C in zymogram development buffer (Novex, Carlsbad,
CA, United States).
In a separate set of experiments, one sample from non-
arthritic and arthritic doxycycline-free experimental groups was
loaded into the gel in 4 replicates. After renaturation, the gel was
cut into 4 pieces, which were separately incubated in development
buffer containing doxycycline hyclate at 0, 0.05, 0.1, or 0.2µg/mL
concentrations, respectively, in accordance with the plasma levels
of the doxycycline-treated animals. In another setup 3 pieces
of the gel were separately incubated with 2, 20, or 200 µg/mL
doxycycline hyclate in comparison with the previously applied
0 and 0.2 µg/mL concentrations to reveal whether these higher
concentrations above the originally measured plasma levels are
able to inhibit MMP activity.
Gels were then stained with 0.05% Coomassie brilliant blue
(Sigma-Aldrich, St. Louis, MO, United States) in a mixture
of methanol-acetic acid-water [2.5:1:6.5 (v/v)] and destained
in aqueous 4% methanol-8% acetic acid (v/v). Gelatinolytic
activities were detected as transparent bands against the dark-
blue background. Gels were scanned in a transilluminator and
band intensities were quantified by Quantity One software
(BioRad, Hercules, CA, United States), and expressed as the
ratio to the internal standard, and presented in arbitrary units.
For positive controls, gelatinase zymography standard containing
human MMP-2 and -9 (Chemicon Europe Ltd., Southampton,
United Kingdom) was used. For negative control, lanes
containing tissue samples were cut off after renaturation and were
separately incubated for 20 h at 37◦C in development buffer in
the presence of the calcium chelator EGTA [ethylene glycol-bis(2-
aminoethylether)-N,N,N′,N′-tetraacetic acid; 10 mM]. Since no
gelatinolytic activities could be seen at all, we concluded that the
all visible bands derive from MMP activities (data not shown).
Measurement of Water Consumption and
Plasma Concentration of Doxycycline
Mice were kept with a maximum of 8 mice/cage density. Water
consumption was measured every other day by weighing the
water bottles and measuring the volume of the residual water for
each cage until day 30. At the end of both series of the experiment,
on days 16 and 30, animals were euthanized with sodium
pentobarbital (100 mg/kg i.p.) and blood was taken by cardiac
puncture to analyze the plasma concentrations of doxycycline.
The plasma concentrations were determined by liquid
chromatography-mass spectrometry (LC-MS) system
(Ruz et al., 2004). Stock solutions of doxycycline hyclate,
oxytetracycline hydrochloride (≥95%; Sigma-Aldrich, St. Louis,
MO, United States) and calibration standards were prepared
by weighing 10 mg of the reference standards. These were
transferred to individual 10 mL volumetric flasks, diluted with
solvent mixture (1% (v/v) acetic acid in methanol:water = 20:80)
to obtain a concentration of 1 mg/mL, and stored at 2–8◦C
protected from light. Solutions of 5000, 2500, 250, 25, 2.5, 1.25,
and 0.625 ng/mL concentrations served as calibration standards.
Plasma samples (300 µL) in Eppendorf tubes (2 mL) were
measured by spiking with 2 µL of 50 ng/mL oxytetracycline
internal standard solution. After mixing, 20 µL of 1 mol/L
trichloroacetic acid (Fluka, Buchs, Switzerland) was added,
vortex-mixed for 1 min and centrifuged for 15 min at 14
500 rpm. The supernatants were transferred to autosampler vials
and 20 µL was injected into the LC–MS–MS system (Agilent
LC-MSD-TRAP-XCT_plus, Santa Clara, CA, United States).
Ionization parameters and ion optics voltages were optimized for
the detection of the oxytetracycline and doxycycline standards
(250 ng/L). The Agilent ChemStation and Agilent LC/MSD
Trap softwares were applied. Linearity, precision, accuracy,
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specificity and stability were validated, all results were within the
acceptable range.
Measurement of Phospholipase A2
Activity and Prostaglandin E2 Level in
the Joint Homogenates
Cytosolic phospholipase A2 (cPLA2) activity was measured
by the colorimetric cPLA2 assay kit (Abcam, Cambridge,
United Kingdom; ab133090; sensitivity: 3.5–42 nmol/min/mL)
from the tibio-tarsal joint homogenates according to the
manufacturer’s protocol. Based on the results of pilot
experiments, our undiluted samples were measured in duplicates.
The absorbance was recorded at 410 nm using a plate reader
(Fluostar Optima, BMG Labtech, Ironmass Consulting Ltd.,
Budapest, Hungary) and the enzyme activity values were
calculated as nmol/min/mL.
Prostaglandin E2 (PGE2) levels from the same homogenates
were measured by a colorimetric ELISA kit (antibodies-
online GmbH, Aachen, Germany; ABIN365349; detection
range: 0.4–80 pg/mL, sensitivity: 0.2 pg/mL) according to the
recommendations of the manufacturer in duplicates at 450 nm
using on the same plate reader. PGE2 concentration values were
calculated as pg/mL by a double logarithmic depiction of the
standard curve followed by regression analysis and fitting the
samples’ absorbance values to the best fit linear regression.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism. Results
were expressed as means ± standard errors of means (S.E.M.).
Arthritis severity, mechanical hyperalgesia, joint function, water
consumption, change of body weight and ex vivo MMP activity
were evaluated by two-way analysis of variance (ANOVA)
followed by Bonferroni’s multiple comparison test, in vivo
luminescence and fluorescence imaging, in vitro MMP activity,
PLA2 activity and PGE2 level measurements by one-way ANOVA
followed by Bonferroni’s multiple comparison test, micro-
CT data by two-way ANOVA followed by Sidak’s multiple
comparison test. In all cases p < 0.05 was considered to be
statistically significant.
RESULTS
Doxycycline Does Not Decrease Either
in vivo or ex vivo MMP Activity in the
Arthritic Ankle Joints
Arthritis induced a significant increase of fluorescent signal
indicating in vivo MMP activity in the ankle joints on day 4,
but significant difference did not occur between the tap water-
and SDD-treated arthritic groups (Figures 2A,B). Sixteen days
after arthritis induction 57–60 kDa MMP isoform, 75 kDa
MMP-2 and 92 kDa MMP-9, but at 30 days only 57–60 kDa
isoform increased significantly in the ankle joint homogenates of
both arthritic groups as compared to the non-arthritic controls
(Figures 3A–I). On day 30, interestingly, remarkably elevated
FIGURE 2 | Doxycycline does not inhibit arthritis-induced in vivo MMP activity
in the ankle joints. (A) Representative fluorescence images illustrating in vivo
MMP activity and (B) its quantitative analysis in the ankle joints of non-arthritic
(n = 3) and arthritic (n = 8) mice treated with doxycycline (80 mg/kg p.o. every
day during the 30 days experimental period) as compared to the non-arthritic
(n = 3) and arthritic (n = 8) tap water-consumed controls 4 days after arthritis
induction. Data are shown as means ± S.E.M. of n = 3–8 mice/group,
∗∗∗p < 0.001 vs. respective non-arthritic controls (one-way ANOVA followed
by Bonferroni’s multiple comparison test).
activity of 92 kDa MMP-9 was observed not only in the tap water-
consumed arthritic, but also in the non-arthritic group, which
was significantly reduced by SDD in both groups (Figure 3I).
Activity of 72 kDa isoform was similar in both non-arthritic and
arthritic groups on both days 16 and 30 (Figures 3C,G).
Doxycycline Does Not Influence
Arthritis-Induced Clinical Signs,
Mechanical Hyperalgesia, and
Joint Function Impairment
Considerable paw edema and hyperemia developed few days
after serum injection in the arthritic groups, which reached its
maximum on day 7. Then the severity of arthritis decreased
slightly by the 2nd boost injection (day 10), which stabilized
the disease symptoms. After day 17 the clinical score decreased
steeply and despite the 3rd boost injection inflammation did not
increase remarkably (Figure 4A). Mechanical hyperalgesia (tap
water consuming arthritic group: from 8.81± 0.1 to 6.99± 0.36 g,
doxycycline-treated arthritic group: from 8.93 ± 0.09 to
6.79 ± 0.25 g) and the time spent on the grid were significantly
reduced 5 days after arthritis induction and remained unchanged
during the 30 days experimental period (Figures 4B,C). SDD
treatment did not influence any of the parameters, the severity of
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FIGURE 3 | Doxycycline does not inhibit arthritis-induced ex vivo MMP activity
in the ankle joints. (A) Representative gel image illustrating ex vivo MMP
activity from homogenized mouse ankle joints 16 days after arthritis induction.
(B–E) Quantitative analysis of MMP activity in the ankle joints of non-arthritic
control and arthritic mice treated with doxycycline (80 mg/kg p.o. every day
during the 16 days experimental period) compared to the non-arthritic control
and arthritic controls consuming tap water 16 days after arthritis induction.
(F–I) Quantitative analysis of ex vivo MMP activity in the ankle joints of
non-arthritic control and arthritic mice treated with doxycycline (80 mg/kg p.o.
every day during the 30 days experimental period) compared to the
non-arthritic control and arthritic controls consuming tap water 30 days after
arthritis induction. Data are shown as means ± S.E.M of n = 2–5 mice/group,
∗p < 0.01, ∗∗p < 0.001, ∗∗∗p < 0.0001 vs. respective non-arthritic controls;
#p < 0.01 vs. respective tap water consuming mice (two-way ANOVA
followed by Bonferroni’s multiple comparison test).
clinical signs, the mechanical hyperalgesia and the joint function
impairment were similar to the tap water consuming arthritic
mice (Figures 4A–C).
FIGURE 4 | Doxycycline has no effect on K/BxN serum-induced joint
inflammation, mechanical hyperalgesia and grasping ability deterioration.
Alterations of the (A) semiquantitative clinical score, (B) mechanonociceptive
threshold, and (C) time spent on the grid in arthritic (n = 13) and non-arthritic
(n = 5) mice treated with doxycycline (80 mg/kg p.o. every day during the 30
days experimental period) as compared to tap water consuming arthritic
(n = 12) and non-arthritic animals (n = 3). Data are shown as means ± S.E.M.
of n = 3–13 mice/group, ∗p < 0.05 vs. respective non-arthritic controls
(two-way ANOVA followed by Bonferroni’s multiple comparison test).
Doxycycline Does Not Influence the
Neutrophil MPO Activity and Plasma
Extravasation in the Arthritic Ankle
Joints
Both arthritic groups showed intensive luminol-derived
bioluminescence signal in the ankle joints reaching the
maximum on day 2, but SDD had no inhibitory effect at any
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FIGURE 5 | Doxycycline does not alter arthritis-induced neutrophil MPO activity and plasma extravasation. (A) Representative bioluminescence and (B) fluorescence
images illustrating MPO activity and plasma extravasation, respectively, and (C,D) their quantitative analysis in the ankle joints of arthritic mice treated with
doxycycline (80 mg/kg p.o. every day during the 30 days experimental period; n = 13) as compared to the tap water consuming controls (n = 12) on days 0, 2, 8, 14,
and 21. Data are shown as means ± S.E.M. of n = 12–13 mice/group, ∗∗p < 0.001, ∗∗∗p < 0.001 vs. respective day 0 controls (one-way ANOVA followed by
Bonferroni’s multiple comparison test).
of the time points (Figures 5A,B). Plasma extravasation was
similarly high in the arthritic ankle joints of both groups in the
early phase, which increased further until day 8, then decreased
slightly until day 21. However, significant difference was also not
observed between the groups (Figures 5C,D).
Doxycycline Significantly Increases
Trabecular Connectivity and Reduces
Bone Mineral Density in the
Periarticular Region
The arthritis induced a marked irregularity of the ankle bones,
narrowing of the tibio-tarsal joints, and widespread erosions,
visually apparent on both CT slices and 3D reconstructions
(Figures 6A, 7A). This was reflected by the quantitative analysis,
which revealed that the number and volume of open and all pores
increased significantly due to arthritis regardless of treatment
with SDD in the ankle region (Figures 6B–D). Open and total
pore volume also increased in the distal tibia (Figures 7D,E).
Bone mineral density decreased in the periarticular region in
SDD-treated mice, but not in their tap water consuming controls
(Figure 7B). Bone surface density increased in both groups in
the distal tibia, highlighting the marked osteophyte formation
(Figure 7C). The Euler number, a measure of bone structural
connectedness was significantly greater in SDD-treated animals
in both regions (Figures 6E, 7F).
Chronic Oral SDD Administration Results
in Subantimicrobial Concentration in the
Systemic Circulation
The plasma concentrations of doxycycline ranged from 0.036
to 0.151 µg/mL in the mice drinking the 0.5 mg/mL solution
for 16 or 30 days (Table 1). The water consumption did not
differ between respective tap water consuming and SDD-treated
groups, but it was significantly lower in the arthritic groups as
compared to non-arthritic controls as a sign of general sickness
behavior (Supplementary Figure S1A). The original body weight
of the mice was not significantly different (average 29 g), but
after day 7 significant 15–25% weight loss was observed in
both arthritic groups as compared to the non-arthritic ones.
Furthermore, the weight loss of SDD drinking arthritic mice was
significantly greater than the tap-water consuming arthritic ones
during the period of days 7–10 (Supplementary Figure S1B).
Increased MMP Activity in the Arthritic
Ankle Joint Homogenates Was Not
Influenced by Doxycycline
All examined MMP isoform activities were enhanced in the
doxycycline-free arthritic joint homogenates, but none of them
changed after incubation with 0.05, 0.1, and 0.2 µg/mL
doxycycline, the concentration range measured in the mouse
plasma (Figures 8A–D). Among higher concentrations only the
200 µg/mL concentration which is remarkably above both the
subantimicrobial concentration and the maximal concentration
detected in the plasma, was able to significantly inhibit MMP-9,
but not MMP-2 activity (Supplementary Figures S2A–D).
Doxycycline Does Not Alter cPLA2
Activity and PGE2 Level in the Joints
Based on the observed worsening effect of SDD on arthritic
bone structure deterioration and potential involvement of the
prostanoid system in bone metabolism, we measured cPLA2
activity and PGE2 levels in the tibio-tarsal joint homogenates.
On day 16 PLA2 activity, but not PGE2 concentration increased
significantly in the arthritic joint homogenates of the tap
water drinking group as compared to non-arthritic controls.
In the late phase (day 30), neither cPLA2 activity, nor PGE2
concentrations were significantly elevated in the arthritic joints.
SDD treatment did not influence these parameters at either
timepoints (Supplementary Figure S3).
Frontiers in Pharmacology | www.frontiersin.org 8 March 2019 | Volume 10 | Article 233
fphar-10-00233 March 18, 2019 Time: 15:6 # 9
Horváth et al. Doxycycline Worsens Arthritic Bone Microarchitecture
FIGURE 6 | Doxycycline treatment does not affect arthritis-induced bone erosions around the ankle, but increased cancellous bone connectivity. (A) Representative
sagittal CT slices of the ankle joints, (B) change of the number of pores, (C) volume of open pores, (D) the total volume of pores, and (E) the Euler number. Data are
shown as means ± S.E.M. of n = 6–7 mice/group, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. respective day 0 control, #p < 0.05 vs. tap water consuming mice
(two-way ANOVA followed by Sidak’s multiple comparison test).
DISCUSSION
We showed here the increase of various MMP activities
in the joints by in vivo fluorescence imaging together with
ex vivo zymography, as well as investigated their functional
significance using the broad spectrum MMP inhibitor SDD in the
translational mouse model of RA. This is the first demonstration
that SDD alters arthritic bone microarchitecture most probably
independently of MMP inhibition.
Various MMP activities and their functional significance were
examined in the K/BxN serum-transfer arthritis model, which is
particularly appropriate to investigate the innate immune system-
mediated effector phase and the chronic neuropathy-like pain
component of arthritis (Korganow et al., 1999; Christianson
et al., 2010). However, there are only two papers studying the
role of specific MMPs in this model. The first paper shows
that MMP-8 deficiency increases joint inflammation and bone
erosion suggesting the protective role of MMP-8, while the
second one demonstrates that the lack of MMP-13 decreases
TABLE 1 | Water consumption (mL/day/mouse; mean ± S.E.M.; n = 3–13
mice/group) and plasma doxycycline concentration (µg/mL; mean ± S.E.M.).
Water consumption Plasma doxycycline
Group Treatment (mL/day/mouse) concentration (µg/mL)
Control Tap water 8.05 ± 0.33 n.a.
Doxycycline 6.97 ± 0.26 0.066 ± 0.002
Arthritic Tap water 4.09 ± 0.27 n.a.
Doxycycline 3.79 ± 0.21 0.071 ± 0.002
Consumption and plasma concentration data represent 3 mice in non-arthritic
control, 12 mice in arthritic tap water-consumed group, 5 mice in non-arthritic
control, 13 mice in arthritic doxycycline-treated group.
both clinical and histological severity of arthritis indicating the
promoting function of MMP-13 in the disease (Garcia et al., 2010;
Singh et al., 2013).
In order to obtain a deeper and more complex insight about
the activity and roles of various MMPs in this model, we
applied integrative in vivo and in vitro methodology. Significantly
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FIGURE 7 | Doxycyline treatment decreases bone mineral density in the periarticular region of the distal tibia, while increasing trabecular connectivity, but has no
effect on the formation of arthritic bone erosions. (A) Representative 3D micro-CT reconstructions of the right ankle joints, (B) bone mineral density, (C) bone surface
density, (D,E) open and total pore volume, and (F) Euler number. Data are shown as means ± S.E.M. of n = 6–7 mice/group, ∗∗p < 0.01, ∗∗∗p < 0.001 vs.
respective day 0 control, #p < 0.05 vs. tap water consuming mice (two-way ANOVA followed by Sidak’s multiple comparison test).
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increased MMP activity in the arthritic ankle joints was observed
in vivo using a non-selective fluorescent imaging dye sensitive
for MMP-2, -3, -7, -9, -12, and -13. In accordance with these
findings, enhanced activities of a 57–60 kDa MMP, 75 kDa
MMP-2, and 92 kDa MMP-9 isoforms were shown from the
arthritic ankle joint homogenates by gelatin zymography ex vivo.
The increased gelatinase activity at the band of 57–60 kDa was
particularly surprising. There are three possible types of MMPs
(proMMP-1, -3, and -13) that this can be related to, but the most
likely candidates are proMMP-3 and proMMP-13. ProMMP-
3 is secreted as a 57 kDa form, which can be glycosylated
resulting in a 60 kDa protein (Wilhelm et al., 1987). Its presence
is further suggested by the fact that it was also purified from
human rheumatoid synovial fibroblasts (Okada et al., 1986). The
molecular weight of the proMMP-13 is also 60–65 kDa. Its active
form (MMP-13) is 50–55 kDa in size, but it is further cleaved into
a final active form of 48 kDa (Freije et al., 1994; Knauper et al.,
1996). MMP-13 is expressed by human chondrocytes (Blavier and
Delaisse, 1995; Borden et al., 1996; Mitchell et al., 1996; Reboul
et al., 1996), synovial membrane (Wernicke et al., 1996), synovial
stroma (Lindy et al., 1997), and synovial fibroblasts (Westhoff
et al., 1999). ProMMP-1 is also a potential candidate on the basis
of the molecular weight, but its presence in the gel is unlikely,
because MMP-1 cleaves gelatin about 40 times less effectively than
MMP-13 (Knauper et al., 1996). It is worth mentioning that the
mouse and human type MMP-1 are not the same, in mice the
equivalent of human MMP-1 is MMP-1a, which is structurally
similar, but differently expressed (Foley and Kuliopulos, 2014).
Overall, we suggest that the 57–60 kDa gelatinase activity refers
to proMMP-3 and/or proMMP-13 isoforms, although it could
accurately be determined only by mass spectroscopy.
Several data support the relevance of these MMP isoforms
in the pathogenesis of human and experimental RA. In RA
patients, MMP-1 and MMP-3 in the serum, synovial tissue (ST)
and fluid (SF), MMP-2 and MMP-7 in the SF, MMP-9 in the
plasma and SF, MMP-12 and MMP-13 in the ST and SF have
already been detected (Ahrens et al., 1996; Wernicke et al.,
1996; Yoshihara et al., 2000; Moore et al., 2000; Tolboom et al.,
2002; Green et al., 2003; Tchetverikov et al., 2003; Liu et al.,
2004). In some cases, their distinct roles were also described in
animal models. In a previous study, genetic ablation of MMP-
2 resulted in an exacerbated level of collagen antibody-induced
arthritis, while the lack of MMP-9 attenuated it compared to the
wildtype mice indicating suppressive role of MMP-2 and pro-
inflammatory role of MMP-9 in the process (Itoh et al., 2002).
Interestingly, despite the convincing human data, the role of
MMP-3 could not be confirmed in animal models, since disease
severity was not altered in MMP-3-deficient mice in two antigen-
induced arthritis models (Mudgett et al., 1998; van Meurs et al.,
1999). In contrast, MMP-12-null mice showed more extensive
articular inflammation and cartilage destruction associated with
massive neutrophil infiltration in the collagen-induced arthritis
(CIA) model suggesting the protective role of macrophage-driven
MMP-12 in RA (Bellac et al., 2014). The deleterious role
FIGURE 8 | Doxycycline does not inhibit in vitro MMP activity in the arthritic joint homogenates. Changes of in vitro gelatinolytic activity of (A) 57–60 kDa, (B) 72 kDa,
(C) 75 kDa, and (D) 92 kDa MMP isoforms in the arthritic and the non-arthritic control joint homogenates incubated with 0.05, 0.1, and 0.2 µg/mL doxycycline
compared to the native control. Data are shown as means ± S.E.M. of n = 4 samples/group (one-way ANOVA followed by Bonferroni’s multiple comparison test).
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of MMP-13 was also proven with gene-deficient mice and a
highly selective inhibitor. MMP-13 deficiency in the K/BxN
serum-transfer arthritis model, as well as selective MMP-13
inhibitor treatment in severe combined immunodeficiency and
CIA models resulted in significantly reduced joint inflammation
and cartilage destruction (Jungel et al., 2010; Singh et al., 2013).
Since we have detected significantly increased K/BxN serum-
induced MMP activation with both in vivo optical imaging and
gelatin zymography, we investigated their functional relevance
in the model with the widely used non-selective inhibitor SDD.
Doxycycline belongs to the tetracycline family, whose MMP-
inhibitory effect in subantimicrobial dose has been known for
three decades (Greenwald et al., 1987). After decades of research
its precise inhibitory mechanisms were also identified, it blocks
primarily MMP activity by the chelation of the catalytic zinc
and altering enzyme conformation, but also suppresses their gene
expression and the proteolytic activation (Golub et al., 1998;
Smith et al., 1999). Although 50% inhibitory concentrations of
tetracyclines ranging from 5 to 500µM had been shown to inhibit
MMP-1, -2, -8, -9, and -13 in vitro, only MMP-13 activity was
reduced by 5 µM doxycycline bioavailable in the tissues after oral
administration (Smith et al., 1999). Due to its unique feature, i.e.,
the lack of antimicrobial actions, SDD became one of the main
pathways of the development of synthetic MMP inhibitor drugs.
Moreover, it was already approved by the U.S. Food and Drug
Administration for the treatment of chronic periodontitis and
acne rosacea (Golub et al., 2016). There are only few literature
data when tetracyclines including doxycycline were administered
in arthritis models and there are no papers for its chronic
use. Oral tetracycline treatment suppressed metalloproteinase
activity in arthritic tissue, but even very high doses failed
to exhibit substantial anti-inflammatory efficacy (reduce joint
swelling or paw diameter) in adjuvant-induced arthritis of the rat
(Greenwald et al., 1992). Furthermore, acute oral pretreatment
with doxycycline (3, 10, and 30 mg/kg) in an acute antigen
(modified Bovine Serum Albumin)-induced arthritis model of
the mouse dose-dependently inhibited mechanical hyperalgesia
(Pinto et al., 2010). Clinical trials also proves its efficacy in
arthritis (Greenwald, 2011; Golub et al., 2016), but primarily due
to the lack of selectivity it did not become a widely used drug in
RA therapy. However, it is a valuable tool to investigate the roles
of arthritis-related MMPs in preclinical research.
In our study, despite the predictable daily water consumption
of the mice and reaching subantimicrobial plasma concentration
(Table 1), SDD did not inhibit either the in vivo MMP
activity or the ex vivo activity of gelatinases derived from
the arthritic ankle. The latter result has been confirmed by
incubating the arthritic joint homogenates with three different
doxycycline concentrations according to the plasma levels
measured from the SDD-treated animals. When testing higher,
antimicrobial concentrations of doxycycline much above the
highest plasma concentration measured in our study, only the
highest concentration was able to significantly inhibit MMP-9,
but not MMP-2 activity. These results are in good accordance
with similar data, which we obtained in lung and heart
derived from mice chronically exposed to cigarette smoke, where
SDD treatment did not alter MMP activity ex vivo. However,
in vitro treatment only with the highest plasma concentration
measured from SDD-treated animals (0.24 µg/mL) was able
to significantly decrease MMP-9, but not MMP-2 activity in
the lung. Meanwhile, in the heart, none of the doxycycline
concentrations decreased MMP-2 activity similarly to the joints
(unpublished data). Although plasma doxycycline concentrations
have been reliably determined, one limitation of this study
is that we could not measure the tissue concentration of
doxycycline in the joint homogenates due to technical difficulties.
In accordance with MMP activity results none of the K/BxN
serum-induced mechanical hyperalgesia, clinical signs, joint
function impairment, neutrophil MPO activity and vascular
hyperpermeability were altered by the SDD treatment.
Although characteristic functional symptoms accompanied
by significantly increased MMP activity in the joints cannot be
inhibited by SDD treatment in our chronic arthritis model, it
has profound effects on inflammatory homeostatic imbalance
of the bones. In our study significant decrease of bone
mineral density, which is also a hallmark clinical feature of
human RA, was only demonstrated in the region of the distal
tibia of SDD-treated mice. Open porosity representing bone
erosions increased in K/BxN serum-transfer arthritis model
similarly in both SDD and tap water consuming animals. Bone
surface density only increased significantly in the distal tibia,
which can be explained by the osteophyte-formation in this
region. Arthritis was accompanied by an increased trabecular
connectivity in both distal tibia and ankle that is likely to
reflect bone neoformation due to inflammation. SDD treatment
further significantly enhanced this parameter in both regions of
arthritic mice as compared to their tap water consuming controls
suggesting that SDD treatment results in detrimental overall
effect as shown by aggravated periarticular bone resorption and
reactive bone remodeling.
Previous studies have shown no effects of SDD on bone
architecture under healthy conditions (Fowlkes et al., 2015),
but profoundly improved bone homeostasis in ovariectomy-
induced osteopenia by inhibiting not only MMPs, but other
collagenases involved in bone resorption (Pytlik et al., 2004).
Furthermore, doxycycline can shift the bone homeostasis toward
the osteoblastic pathway by directly inhibiting osteoclasts and
facilitating their apoptosis via inhibiting the Dickkopf-related
protein 1 (Dkk-1) pathway (Gomes et al., 2017). Since Dkk-1
overexpressing mice display an osteopenic phenotype, and anti-
Dkk-1 antibody treatment prevents bone loss in experimental
OA, interference with these signaling pathways is likely to be
involved in the increased trabecular connectivity observed in
SDD-treated mice in our experiment (Funck-Brentano et al.,
2014). Another potential mechanism of SDD on arthritic bone
structure deterioration may be PLA2 inhibition and the decreased
level of PGE2, which plays an important role in bone metabolism
(Lisowska et al., 2018). It is well-known that tetracyclines inhibit
PLA2 activity and can theoretically decrease PGE2 level in bones
(Pruzanski et al., 1992, 1998), but our present results did not
confirm this concept. PLA2 activity, but not PGE2 concentration
increased significantly in the arthritic joint homogenates of the
tap water drinking group on day 16, when stable inflammatory
symptoms such edema and hyperemia were present as compared
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to non-arthritic controls. In the late phase (day 30), when
the inflammation was over and the arthritic bone structure
deterioration was observed, neither PLA2 activity, nor PGE2
levels elevated. However, SDD administration did not influence
these parameters at either timepoint.
CONCLUSION
In conclusion, K/BxN serum-transfer arthritis model is
characterized by significantly increased MMP levels, but the
widely used non-selective MMP inhibitor SDD is not likely to
inhibit MMP activity in the joints. SDD clearly worsens the
chronic arthritis-induced bone microarchitectural alterations in
a complex manner by simultaneously decreasing mineralization
and increasing the trabecular connectivity.
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FIGURE S1 | (A) Water consumption (mL/day/mouse) and (B) percentage change
of body weight (%). Data are shown as means ± S.E.M. of n = 3–13 mice/group,
∗p < 0.05 vs. respective non-arhritic control mice, ###p < 0.001 vs. tap water
consuming arthritic mice (two-way ANOVA followed by Bonferroni’s multiple
comparison test).
FIGURE S2 | Doxycycline in high concentration (200 µg/mL), but not in lower
ones inhibits in vitro MMP-9 activity in the arthritic joint homogenates. Changes of
in vitro gelatinolytic activity of (A) 57–60 kDa, (B) 72 kDa, (C) 75 kDa, and (D)
92 kDa MMP isoforms in the arthritic and the non-arthritic control joint
homogenates incubated with 0.2, 2, 20, and 200 µg/mL doxycycline compared to
the native control. Data are shown as means ± S.E.M. of n = 4 samples/group,
∗p < 0.05 vs. native control (one-way ANOVA followed by Bonferroni’s multiple
comparison test).
FIGURE S3 | (A) Cytosolic phospholipase A2 activity and (B) prostaglandin E2
levels of tibio-tarsal joint homogenates. Data are shown as mean ± S.E.M. of
n = 3–7/group, ∗∗p < 0.01 vs. respective non-arthritic controls (one-way ANOVA
followed by Bonferroni’s multiple comparison test).
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